Rocket Pharmaceuticals Gains FDA Accelerated Approval for Kresladi in Pediatric LAD-I Gene Therapy

Rocket Pharmaceuticals' accelerated approval of Kresladi (marnetegragene autotemcel) for pediatric severe Leukocyte Adhesion Deficiency Type I marks the first lentiviral vector-based gene therapy cleared by the FDA for this indication, and the CMC flexibility language attached to the approval carries direct implications for regulatory affairs teams building submissions in rare disease biologics.

The FDA's Center for Biologics Evaluation and Research confirmed the approval on March 26, 2026, for patients with biallelic ITGB2 variants who lack an HLA-matched sibling donor for allogeneic hematopoietic stem cell transplant. In the agency's own statement, CBER director Vinay Prasad noted that the FDA applied regulatory flexibilities across both CMC and clinical review, explicitly citing small patient populations and all available evidence sources as acceptable inputs under its scientific standards. For QA directors and regulatory leads, that framing is a documented agency position, not an informal signal, one worth referencing when structuring CMC packages for comparable rare disease gene therapy programs.

The approval also triggered a Rare Pediatric Disease Priority Review Voucher, which Rocket subsequently agreed to sell for $180 million on April 28, 2026. The company characterizes the proceeds as nondilutive capital, with cash runway now projected through the second quarter of 2028. Those funds are earmarked for three cardiovascular gene therapy programs: Danon disease, PKP2-associated arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy.

For plant heads and manufacturing leads, Kresladi's autologous hematopoietic stem cell platform introduces the process complexity typical of patient-specific biologics, each batch tied to a single pediatric recipient, with sterility assurance and release testing timelines compressed against clinical urgency. The accelerated approval pathway means post-marketing confirmatory data obligations remain active, and CMC commitments made at the time of licensure will be subject to ongoing FDA scrutiny as the program scales.

The $180 million PRV transaction closes a financing loop that directly funds the next wave of Rocket's IND-stage cardiovascular programs, making the confirmatory trial timeline for Kresladi a pressure point: any post-market study delays could affect both the product's full approval status and the credibility of the pipeline it is now underwriting.

Source: CGTLive via cgtlive.com, May 7, 2026.